← Back to the full Peptide Guide overview
Important Disclaimer — Read Before Using This Page
This information is not intended for use by unlicensed individuals or by licensed professionals who lack adequate training and experience in assessing patients for peptide or hormone therapy. All clinical decisions and dosing must be made in consultation with a licensed, experienced physician and a licensed, experienced compounding pharmacist, and should be supported by published clinical studies.
The information presented here has been compiled using Artificial Intelligence, statements from videos and websites by apparent qualified professionals, and available published research. We strongly encourage exhaustive independent research before considering any therapy. Anyone starting a medication they have never taken before should take an extremely conservative approach.
Nothing on this page or in these videos should be taken as medical advice. These materials are provided only to help begin your research. All dosing and treatment decisions should be made between you and your medical providers after proper evaluation. We are not affiliated with any of the doctors whose videos appear on this page.
Tirzepatide FDA-Approved
Generic for: Mounjaro, Zepbound
Category: Dual GLP-1/GIP Receptor Agonist — Weight Management & Type 2 Diabetes
How it works. Tirzepatide is a dual receptor agonist that engages both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. It is not simply a stronger version of semaglutide—the addition of GIP activation appears to enhance insulin sensitivity, change appetite signaling in ways distinct from pure GLP-1 activation, and potentially improve lipid handling. The dual mechanism produces a broader incretin-based metabolic effect than GLP-1 activation alone.
Why a physician prescribes it. A doctor may reach for tirzepatide when a patient needs more aggressive weight loss, has type 2 diabetes, has plateaued on semaglutide, or requires a stronger metabolic intervention. Greater efficacy also brings greater responsibility: patients who lose 20–25% of their body weight can lose significant lean mass, alter their gallbladder dynamics, and shift the way they metabolize other medications. The goal is the lowest effective dose the patient can tolerate—not the maximum labeled dose. Many patients hit their weight-loss target at 5–10 mg weekly and never need the 15 mg ceiling.
What to know before starting. The safety profile overlaps with semaglutide: same class-level cautions around thyroid carcinoma and MEN-2, pancreatitis, gallbladder disease, dehydration, and hypoglycemia when combined with insulin or sulfonylureas. GI intolerance can be more pronounced at higher doses. Because delayed gastric emptying changes the absorption of anything taken by mouth, tell your prescriber about every oral medication you are on. And once again: expect a serious conversation about protein intake and resistance training so the weight you lose is fat, not muscle.
Recommended Videos
Dr. Craig Koniver — Huberman Lab — Peptide & Hormone Therapies for Health, Performance & Longevity
Dr. Meghan, MD — Weight Medicine — Mounjaro/Zepbound — Stomach Paralysis? (Obesity Doctor)
Dr. Meghan, MD — Weight Medicine — Tirzepatide + Metformin — How To Combine? (Obesity Doctor)
Video Sources & Independence
The videos linked on this page are provided solely for educational purposes. None of the physicians or channels featured are sponsored by, affiliated with, or compensated by NJ Weight Loss & Preventive Care Clinics, its physicians, or any individuals associated with our practice. We have selected these videos because they offer thoughtful, evidence-based discussion of mechanisms and clinical considerations. Viewers should evaluate all sources independently.
← Back to the full Peptide Guide overview · Peptide Dosing Reference →